Pharmaceuticals

Yuyu Pharma appoints Robert Wonsang Yu as incoming President and CEO

SEOUL, South Korea, April 5, 2020 /PRNewswire/ -- Yuyu Pharma (KRX: 000220), a global pharmaceutical company based in Korea, is pleased to announce the appointment of Mr.Robert Wonsang Yu as President and Chief Executive Officer effectiveApril 6, 2020.

2020-04-06 08:00 159

Yuyu Pharma introduces enhanced ERP system

SEOUL, South Korea, March 31, 2020 /PRNewswire/ -- Yuyu Pharma (CEO Robert Wonsang Yu, KRX 000220) introduced a new Enterprise Resource Planning (ERP) system to identify real-time management conditions and enhance system management for more efficient decision-making.

2020-03-31 21:00 312

Fosun Pharma Announces 2019 Annual Results

SHANGHAI, March 31, 2020 /PRNewswire/ -- On March 30 2020, Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading healthcare group in China, announced its annual results for the year 2019 ("the reporting period"). During the reporting period: ...

2020-03-31 17:51 5573

3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar 45.2%

HONGKONG, March 31, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2019 annual results, showing that the Company maintained steady growth, with core products continuously leading the market and more products being included into drug reimbursemen...

2020-03-31 12:29 4971

Alphamab Oncology, Simcere and 3D Medicines Announce Partnership to Develop and Commercialize Subcutaneous Injectable anti-PD-L1 Antibody for Oncology Indications in Mainland China

SUZHOU, China, March 30, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced today that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab"), a wholly-owned subsidiary of the Company, has established strategic partnership with Simcere and 3D Medicines (Beijing) Co....

2020-03-30 19:00 2521

Ascentage Pharma Releases 2019 Annual Results, Reports Increased Investment in R&D and Advances in Global Clinical Development

SUZHOU, China and ROCKVILLE, MD, March 29, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released its annual results for the...

2020-03-30 08:00 788

GenScript ProBio Congratulates XlifeSciences on the Start of TAEST16001 Early Phase Clinical Trial

NANJING, China, March 27, 2020 /PRNewswire/ -- Guangzhou XlifeSciences, a partner of GenScript ProBio (GenScript's CDMO segment) announced that the early phase clinical trial of TAEST16001 project has been started. GenScript ProBio extends congratulations on this. This clinical trial project is ...

2020-03-27 21:00 1420

Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib)

SUZHOU, China, March 27, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced today that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab"), a wholly-owned subsidiary of the Company, has entered a clinical supply agreement with Pfizer Inc. ("Pfizer") to advance a ...

2020-03-27 19:00 3483

Luye Pharma Continues to Deliver Strong Growth in 2019

SHANGHAI, March 27, 2020 /PRNewswire/ -- Luye Pharma Group (02186.HK) reported its financial results for 2019 onMarch 27, 2020. According to the results, the company has achieved a total revenue ofRMB 6.358 billion, up 22.9% year-on-year. EBITDA wasRMB 2.488 billion, up 26.9% year-on-year; and n...

2020-03-27 16:44 4009

CStone submits new drug application for the targeted therapy avapritinib in Taiwan for the treatment of adults with advanced PDGFRA exon 18 mutant gastrointestinal stromal tumor

SUZHOU, China, March 27, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for avapritinib, a precision therapy being developed for the t...

2020-03-27 14:02 717

Fosun Pharma's Novel Coronavirus Nucleic Acid Detection Kit Receives Emergency Approval from China NMPA

SHANGHAI, March 26, 2020 /PRNewswire/ -- Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March"), a wholly-owned subsidiary ofShanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), has received emergency approval from the National Medica...

2020-03-26 22:27 4602

Bio-Pharm Solutions Expands from Epilepsy to Neurodegenerative Diseases Aiming for IPO

SUWON, South Korea, March 26, 2020 /PRNewswire/ -- Bio-Pharm Solutions Co., Ltd. has expanded its clinical pipelines from infantile spasms (IS) to status epilepticus (SE) and Alzheimer's disease. Based on the performance of its first pipeline, an infantile spasms drug, BIo-Pharm Solutions is c...

2020-03-26 21:00 509

Happiness Biotech Announced Breakthrough in Developing Covid-19 Testing Kits

NANPING, China, March 25, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that the Company, together with Fuzhou University, have achieved a breakthrough in developing Cov...

2020-03-25 20:00 3742

Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

SHENZHEN, China, March 24, 2020 /PRNewswire/ -- On March 23th, 2020, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's application for Investigational New Drug (IND) of CS12192 has been accepted by Center for Drug Evaluation, ...

2020-03-24 19:25 659

Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States

SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the global Phase Ib/I...

2020-03-24 12:30 2997

Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States

SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the global Phase Ib/I...

2020-03-24 12:24 3046

Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States

SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the global Phase Ib/I...

2020-03-23 19:00 956

Hansoh Pharma's Ameile (Almonertinib) Receives Marketing Authorization in China for Second-Line Treatment for Patients With EGFR T790M-Mutation Non-Small Cell Lung Cancer

SHANGHAI, March 19, 2020 /PRNewswire/ -- Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma"), a leading biopharmaceutical company inChina, announced that the National Medical Products Administration (NMPA) has granted marketing authorization for AMEILE (almonertinib, previously also kno...

2020-03-19 19:00 4782

ChemPartner Introduces New State-of-the-Art Global Operation Center in Shanghai

SHANGHAI, March 17, 2020 /PRNewswire/ -- Shanghai ChemPartner announced the opening of a new, state-of-the-art,24,000 m2 laboratory facility in the Zhangjiang Hi-Tech Park inShanghai, China. The building, operating as ChemPartner's new Global Operation Center, houses approximately 700 employees ...

2020-03-17 23:07 856

Samsung Biologics expands presence in Greater China Region with CDO partnership for Alzheimer's candidate

SONGDO, South Korea, March 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) entered into a contract development and manufacturing agreement with APRINOIA Therapeutics to develop an anti-tau monoclonal antibody candidate to treat primary and secondary tauopathies, including Progressive Supr...

2020-03-17 08:04 671
12345 ... 43